linjc16/ctgov huggingface dataset:
Short Segment Fixation in Thoracolumbar Osteoporotic Fracture

Study Overview
=================
Brief Summary
-----------------
Although long-segment posterior spinal fixation might provide more rigid fixation, the procedure increases perioperative morbidities in the elderly. The present study reviews the results of short-segment decompression and reconstruction in thoracolumbar fragile fractures.

Detailed Description
-----------------
This study included 20 elderly patients with osteoporotic thoracolumbar burst fractures and neurological compromise. The participants were followed-up for a period of 40.6 (24-68) months. A visual analog scale (VAS) and the Oswestry Disability Index (ODI) were used to measure back pain and disability. Radiologic assessment and neurological status were also analyzed.

Official Title
-----------------
Short-segment Decompression and Reconstruction for Thoracolumbar Osteoporotic Fractures With Neurological Deficits: Clinical and Radiological Results of Minimum 2-year Follow-up

Conditions
-----------------
Spinal Fractures

Intervention / Treatment
-----------------
* Procedure: short segment fixation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria osteoporotic burst fracture at a single level of the thoracolumbar region dual-energy X-ray absorptiometry and T-score value less than -2.5 Exclusion Criteria translational displacement at the fracture site (fracture-dislocation) loss of structural integrity within the posterior osteoligamentous complex (such as flexion-distraction ligament disruption) spondylolisthesis of the adjacent vertebrae malignancy chronic steroid administration previous spinal surgery prior vertebroplasty and infection

Ages Eligible for Study
-----------------
Minimum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Oswestry Disability Index (ODI) | Functional outcome after surgery was evaluated using the Oswestry Disability Index (ODI) | at least 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Frankel's grade system | Frankel's grade system was used for assessment of neurologic function | at least 2 years | 
| Local kyphosis and vertebral wedge angle were measured as radiologic assessment (units of measure: degree) | Digital radiographs of the vertebral bodies were reviewed using the picture archiving and communication system (PACS). | at least 2 years | 
| anterior vertebral height | Measurements of the anterior vertebral height (AVH) ratio (% of normal) | at least 2 years |
Acupuncture for Hemiplegic Shoulder Pain

Study Overview
=================
Brief Summary
-----------------
Shoulder pain has been reported to be one of the most common complications after stroke. Several factors have been related to shoulder pain after stroke such as paralysis, restricted range of motion in the shoulder, spasticity, sensory abnormalities, but the relationship between these factors and pain was not discussed. The aim of this study is to identify the efficacy of electroacupuncture in reducing upper limbs spasticity and shoulder pain in stroke patients, and to evaluate the quality of life (QOL) for stroke patients.

Conditions
-----------------
Shoulder Pain in Hemiplegic Side After Stroke

Intervention / Treatment
-----------------
* Procedure: acupuncture
* Procedure: TENS
* Procedure: sham acupuncture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stroke within 6 months from onset Hemiplegia with shoulder pain (VAS > 2) Exclusion Criteria: previous pathology of the shoulder or cardiac pacemaker, and cognition problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EA group<br>To acupuncture the Juanyu (Li15) & Jugu (Li16) with sensation of de-qi, and then give 50 Hz electrical stimulation for 20 minutes. | Procedure: acupuncture<br>* All participants were received regular rehabilitation program, and received different interventions. treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks<br>|
| Experimental: TENS group<br>The electrical patches were placed on the Juanyu (Li15) & Jugu (Li16) or Juanyu (Li15), Quchi (Li11), Shousanli (Li10) & Hegu (Li4), connected to a TENS apparatus and then give 50 Hz electrical stimulation for 20 minutes. | Procedure: TENS<br> <br> |
| Sham Comparator: sham-acupuncutre<br>The Park's Sham Device were placed on the Juanyu (Li15) & Jugu (Li16). | Procedure: sham acupuncture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| shoulder pain degrees | pain VAS in passive shoulder ROM | 10 days after first intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| shoulder ROM | passive shoulder ROM (abduction, ER) | 10 days after first intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
electroacupuncture, TENS, shoulder disorder, hemiplegia
The Effects of Nexium on the Side Effects Associated With a Colonoscopy Prep

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to ascertain if the use of Nexium for 7 days prior to taking a colon prep for a colonoscopy will decrease the side effects that are associated with the colon preparation

Detailed Description
-----------------
The high incidence for colon cancer make it an ideal target for screening. In the United Staes there are approximately 100,00 new cases of colon cancer yearly. Typically the progression from polyps to cancer requires years. This permits a screening procedure to identify polyps befoere they are cancerous. Colon cleansing is required prior to colonoscopy. The gastrointestinal syptoms associted with colonic preps are common and oftn assoicated wwith upper gastrointestinal disorders including GERD, non-ulcer syspepsia, and gastric dysmotoility such as gastropareesis.

Official Title
-----------------
The Effect of Esomeprazole (Nexium) on the Incidence and Severity of Gastrointestinal Adverse Events Associated With a Colonoscopy Purgative

Conditions
-----------------
Nausea, Vomiting, Abdominal Pain

Intervention / Treatment
-----------------
* Drug: esomeprazole (PPI)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject 18 or older undergoing out-patient colonoscopy Exclusion Criteria: Pregnant females Use of protein Pump Inhibitor within last 4 weeks Use of prescription strength H-2 Blocker within last 4 weeks Use of over the counter strength H-2 Blocker greater than 2x's a week Hospitalized patients PEG-EL purgative contraindicated.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: esomeprazole (PPI)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Outcome will be measured by use of a symptom survey utilizing an analog scale. This will be done at the screen visit and prior to colonoscopy. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colonoscopy prep
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Study Overview
=================
Brief Summary
-----------------
To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.

Official Title
-----------------
Phase 2 Study of CP-868,596 + Docetaxel, AG-013736 + Docetaxel, or CP-868,596 + AG-013736 + Docetaxel and of Docetaxel Alone in Patients With Stage IIIb or IV Non-Small Cell Lung Cancer.

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: docetaxel
* Drug: CP-868,596 + docetaxel
* Drug: AG-013736 + docetaxel
* Drug: CP-868,596 + AG-013736 + docetaxel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Platinum-pretreated patients with advanced stage IIIb or IV NSCLC Exclusion Criteria: Centrally-located tumors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: docetaxel|nan|
|Drug: CP-868,596 + docetaxel|nan|
|Drug: AG-013736 + docetaxel|nan|
|Drug: CP-868,596 + AG-013736 + docetaxel|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the anti-tumor efficacy of CP 868,596 plus docetaxel, AG 013736 plus docetaxel, CP 868,596 plus AG 013736 plus docetaxel, and docetaxel alone in patients with advanced NSCLC based on objective tumor response (CR and PR) rate |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determine the safety and tolerability of the combination of daily CP 868,596 and docetaxel on an every 3 week schedule |  |  | 
| Determine the safety and tolerability of the combination of daily AG 013736 and docetaxel on an every 3 week schedule |  |  | 
| Determine the safety and tolerability of both CP 868,596 and AG 013736 given together with docetaxel on an every 3 week schedule |  |  | 
| Assess additional evidence of anti-tumor activity as measured by duration of objective response, progression-free survival, and one-year survival (OS1year) |  |  | 
| Evaluate the pharmacokinetics (PK) of AG 013736 and CP 868,596 when given together with and without docetaxel |  |  | 
| Evaluate the PK of CP 868,596 when given in combination with docetaxel |  |  | 
| Evaluate the PK of docetaxel when given in combination with CP 868,596, or CP 868,596 plus AG 01373 |  |  |
Position of Teamleader and Leadership Performance

Study Overview
=================
Brief Summary
-----------------
Investigation in simulated cardiac arrests. Team leaders are randomly designated. Designated teamleaders are instructed to lead their team from the position of the patient's head or remote from the patient.

Detailed Description
-----------------
participants: physicians taking part in voluntary simulator-based workshops. Teams of 3-4 are formed. One teammember is randomly allocated as teamleader design: prospective, randomized, single-blind, cross-over intervention: teamleaders are randomized and instructed to lead their team from the conventional position at the patient's head or from a remote hands-off position data analysis: will be performed from videorecordings

Official Title
-----------------
Effect of the Position of the Teamleader on Quality of Leadership and Team Performance

Conditions
-----------------
Leadership

Intervention / Treatment
-----------------
* Behavioral: position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Physicians taking part in voluntary workshops Exclusion Criteria: refusal to participate and/or being videorecorded

Ages Eligible for Study
-----------------
Minimum Age: 24 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Conventional position (head position)<br>Leaderposition at the patient's head | Behavioral: position<br>* teamleaders are instructed to allocated position<br>|
| Active Comparator: Remote position<br>Leaderposition remote from patient and hands-off | Behavioral: position<br>* teamleaders are instructed to allocated position<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantity of leadership | Number of leadership utterances made as defined by the adapted Leadership Behaviour Description Questionnaire | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hands-on time | Hands-on time during the first 5 minutes of the cardiac arrest | 5 minutes | 
| Quality of leadership | Type of leadership utterances made as defined by the adapted Leadership Behaviour Description Questionnaire | 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
simulation, cardiopulmonary resuscitation, teamleader
A Multicenter Registry Study of Aneurysmal SAH

Study Overview
=================
Brief Summary
-----------------
Firstly, this study aims at clarifying the current situation of Emergency treatment of aneurysmal subarachnoid hemorrhage (SAH) in China, and analyzing the influencing factors contributing to transport delay, so as to improve the efficiency of emergency treatment; Secondly, comparison and analysis of different surgical treatment of aneurysmal SAH would be undertook, so as to improve the diagnosis and treatment of aneurysmal SAH.

Official Title
-----------------
A Multicenter Registry Study of Aneurysmal Subarachnoid Hemorrhage

Conditions
-----------------
Subarachnoid Hemorrhage, Aneurysmal, Time Delay

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients presented with subarachnoid hemorrhage on CT or lumbar puncture. the intracranial hemorrhage was caused by rupture of aneurysm and was confirmed on CTA、MRA or DSA. patients willing to participate in this clinical trial and attach to regular follow up. Exclusion Criteria: intracranial aneurysm correlating to AVM. dissection, false, traumatic and infectious aneurysms. the rupture of the aneurysm can not be confirmed on CTA、MRA or DSA.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Door to Puncture | the time interval between admission to hospital and puncture | the time interval would be noted and be analyzed through study completion, an average of 6 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Door to CT | the time interval between admission to hospital and time of CT performed | the time interval would be noted and be analyzed through study completion, an average of 6 months. |
The Evaluation of the METS™ Proximal Humeral System

Study Overview
=================
Brief Summary
-----------------
This study is a single centre, non-randomised, post market clinical follow up examining retrospective patient data from a series of surgical cases; which involved the endoprosthetic replacement of the proximal humerus using the Stanmore Implant Worldwide METS (Modular Endoprosthetic Tumour System) Proximal Humeral system. The objective of this study is to evaluate the retrospective patient data where patients have been followed up for at least 12 months post operation; to demonstrate the safety of the METS Proximal Humeral replacement system.

Detailed Description
-----------------
The METS™ Proximal Humeral system is an endoprosthetic replacement designed to restore the length and the function of an arm after the resection of a significant amount of bone tissue; due to a malignant tumour in the proximal humerus. This Post Market Clinical Follow up (PMCF) study is designed to further support the existing evidence that the system is safe and performs as expected, when analysing retrospective patient data that have had a METS™ Proximal Humeral replacement. The target population is male or female subjects aged between 18 years and over who have been implanted with a METS™ Proximal Humeral system at the Royal National Orthopaedic Hospital, Stanmore; and the patient has been followed up for at least 12 months following implantation.

Official Title
-----------------
Post Marketing Clinical Follow Up for the Evaluation of the METS™ Proximal Humeral System Using Retrospective Data

Conditions
-----------------
Complications; Arthroplasty

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient aged 18 and over who has been implanted with a METS™ Proximal Humeral system implant at the Royal National Orthopaedic Hospital, Stanmore. Patient has been followed up for at least 12 months following implant surgery Patient had their surgery on or after January 2007 Exclusion Criteria: Patient is currently or has been involved in pending litigation or worker's compensation Patient has participated in another clinical investigation or study with an investigational medical device within the last 60 days

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| METS Proximal Humeral system<br>Implanted with METS Proximal Humerus | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Evaluation of adverse events that occurred within 12 months post implantation | Adverse events within the first 12 months will be assessed and evaluated | Follow Up of 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Proximal Humerus
International COVID-19 Clinical Evaluation Registry -2 (HOPE-2)

Study Overview
=================
Brief Summary
-----------------
PURPOSE. The main objective of the present study is to carefully characterize the clinical profile of individuals with lasting sequelae after a COVID-19 admission. As secondary objectives, the analysis of the risk-adjusted influence of COVID-19 severity, previous comorbidities and management of patients discharged after COVID-19 will be performed. DESIGN AND STATISTICAL ANALYSIS Cross-sectional and prospective registry, a real life all comers type, with voluntary participation, without specific funding or conflicts of interest. It is a study initiated by researcher that will have advanced statistical support from the IMAS foundation (Institute for the Improvement of Health Care, Madrid, Spain) and the Cardiovascular Research Foundation (FIC, Madrid, Spain). International level. PARTICIPANTS PROTOCOL. The study has been approved by Hospital Clinico San Carlos Ethic´s Committee (21/128-E) and the institutional board of each participating center. The present study proposes the continuation in time of the work previously carried out in the HOPE registry. It proposes to select all the patients attended in any health center (with in hospital beds), who have been discharged or have died up to 31st august 2020. All will be considered eligible with a positive COVID-19 test (any type) or if their attending physicians consider them highly likely to have presented the infection. Given the anonymous characteristics of the registry and the health alarm situation generated by the virus, in principle, it is not considered necessary to provide written informed consent.

Official Title
-----------------
International COVID-19 Clinical Evaluation Registry -2 (HOPE-2)

Conditions
-----------------
Covid19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients discharged (deceased or alive) from any hospital center with a confirmed diagnosis. Exclusion Criteria: There are no exclusion criteria, except for the patient's explicit refusal to participate.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DEATH | Number of participants dead by any cause during follow up. | through study completion, an average of 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Any POSTCOVID-19 symptom | Events defined in HOPE 2 protocol | through study completion, an average of 1 year |
Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to correlate the alimentary consistencies and deglutition disorders in children with cerebral palsy.

Detailed Description
-----------------
Cross-sectional and quantitative study with sample consisted of 50 children with cerebral palsy. The data collection consisted in detection of the main dysphagic manifestations in different consistency of food and types of cerebral palsy.

Official Title
-----------------
Clinical and Instrumental Evaluation of Swallowing in Children With Cerebral Palsy

Conditions
-----------------
Cerebral Palsy, Deglutition Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children with Cerebral Palsy diagnoses were involved, independent from the pre, peri and postnatal factors and from the type of Cerebral Palsy Exclusion Criteria: Children who presented oropharyngelarynx structural abnormality and/or impossibility to feed by oral way

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Palsy, Deglutition, Deglutition disorders, Endoscopy